Avanos Medical (AVNS) Q1 2025: $15M Tariff Hit Forces EPS Reset Despite 9% Nutrition Surge
Avanos’ specialty nutrition segment delivered nearly 9% organic growth, but a $15 million tariff headwind prompted a downward EPS revision and sharpened management’s focus on cost mitigation and strategic flexibility. The new CEO signals a commercial execution reset as the business navigates dynamic macro and regulatory pressures through 2025.
Summary
- Tariff Pressure Forces EPS Reset: Management cut adjusted EPS guidance as tariff costs escalate.
- Nutrition Segment Outpaces Market: Specialty nutrition systems posted standout organic growth and margin gains.
- Leadership Transition Focuses on Execution: New CEO prioritizes commercial strategy and operational discipline amid ongoing transformation.
Performance Analysis
Avanos delivered solid organic sales growth of 2.8% in Q1, led by its rebranded specialty nutrition systems segment, which nearly hit 9% organic growth and reinforced its leadership in long-term, short-term, and neonatal feeding solutions. The pain management and recovery segment also contributed, with normalized organic sales up 2.4%, underpinned by near double-digit growth in radiofrequency ablation (RFA) products. However, surgical pain and game-ready portfolios showed mixed results, with surgical pain declining as expected and game-ready growing at a low single-digit pace.
Profitability was a highlight in the nutrition segment, which saw operating profit expand by 460 basis points to nearly 21%, driven by top-line growth and transformation-driven margin expansion. In contrast, pain management and recovery achieved break-even operating profit, a 400 basis point improvement year-over-year, reflecting ongoing cost discipline and portfolio pruning. Free cash flow reached $19 million for the quarter, with management reiterating a full-year target of $65 million, excluding tariffs.
- Nutrition Segment Margin Expansion: Transformation initiatives boosted nutrition system operating profit by 460 basis points.
- Cash Generation Remains Robust: $19 million in Q1 free cash flow, with full-year guidance held at $65 million pre-tariff.
- Tariff Costs Cloud Profitability: $1.5 million in Q1 tariffs, with $15 million in incremental manufacturing costs projected for 2025.
Despite strong segment performance, the company’s full-year adjusted EPS guidance was cut to $0.75–$0.95 as tariff and one-time executive transition costs weighed on the outlook. Segment-level visibility has improved with the new reporting structure, but macro and regulatory headwinds remain material for the rest of the year.
Executive Commentary
"First and foremost, the transformation efforts made around the portfolio, organization structure, and cost management have laid a strong foundation for enhancing our growth profile, particularly as we look to deploy capital for M&A and partnerships. Additionally, I'm very encouraged by the strong energy and strategic focus I'm seeing across the company."
Dave Pacitti, Chief Executive Officer
"We face significant uncertainty on the ultimate impact of tariffs on our profitability and cash flow. In the first quarter, we incurred $1.5 million of tariffs... If these tariffs remain in effect, we anticipate they will have a material negative impact on earnings for the year. We now estimate approximately $15 million in incremental tariff-related manufacturing costs for the year."
Jason Pickett, Interim Chief Financial Officer and Treasurer
Strategic Positioning
1. Segment Realignment Sharpens Capital Allocation
Avanos’ move to report under two operating segments—specialty nutrition systems and pain management and recovery— reflects a deeper commitment to portfolio focus and disciplined investment. This structure is designed to optimize internal capital deployment, improve ROIC, and provide investors with clearer visibility into segment performance and financial profiles.
2. Transformation Initiatives Embed Cost Discipline
Transformation programs have become core to Avanos’ operations, driving margin expansion, improved demand planning, and lower inventory levels. The company has also embedded a culture of cost management, which is now critical as tariff headwinds mount. These efforts are expected to partially offset external pressures and support ongoing investment in growth and innovation.
3. Commercial Execution and Innovation in Nutrition
The specialty nutrition systems business continues to outperform the market, leveraging product innovation (e.g., CoreDrip tube retention system) and commercial execution to drive growth across long-term, short-term, and neonatal portfolios. The company’s vision to evolve into an integrated specialty nutrition ecosystem underpins its strategy for mid-single-digit organic growth in 2025 and beyond.
4. Pain Management Focuses on RFA and ASC Expansion
The pain management and recovery segment is anchored by strong performance in radiofrequency ablation, supported by renewed ambulatory surgical center (ASC) strategies and new sales structures. International reimbursement tailwinds and procedural shifts to ASCs are creating pockets of growth, particularly for the Ambit product line and Coolief offering. However, surgical pain and HA portfolios remain challenged by pricing pressure and reimbursement changes.
5. Tariff Mitigation and Supply Chain Transition
Tariff exposure, especially on China-origin goods, is a central risk, prompting Avanos to accelerate plans to transition syringe manufacturing out of China by H1 2026. Management is pursuing a mix of mitigation levers, including cost containment, price increases, leveraging trade agreements (USMCA), and seeking further exemptions for key product lines.
Key Considerations
Avanos’ strategic context this quarter is defined by strong segment execution, a sharpened organizational focus, and acute external risk from tariffs and regulatory volatility.
Key Considerations:
- Segment Visibility Improves: New reporting structure enables clearer assessment of growth and margin drivers by business line.
- Tariff Uncertainty Persists: $15 million in anticipated tariff costs could rise further if mitigation efforts underdeliver or if rates remain elevated.
- Transformation Benefits Embedded: Ongoing cost discipline and demand planning improvements are supporting margin expansion and cash flow resilience.
- Capital Flexibility Maintained: Strong balance sheet and cash generation enable continued investment in M&A and transformation, despite external pressures.
- Leadership Reset Underway: New CEO’s commercial focus and experience set the stage for renewed execution and go-to-market innovation.
Risks
Tariff escalation remains the most material risk, with $15 million in incremental costs already forecast and the potential for further increases depending on trade policy developments. Pricing pressure in hyaluronic acid and surgical pain portfolios, as well as macroeconomic and reimbursement volatility, could further constrain margin expansion and cash flow. Leadership transition introduces additional execution risk as new strategies are implemented mid-year.
Forward Outlook
For Q2 2025, management expects:
- Specialty nutrition system segment to soften due to distributor order timing and international Go Direct transition.
- Continued market share gains in RFA within pain management and recovery.
For full-year 2025, management maintained:
- Revenue estimate of $665 million to $685 million.
- Free cash flow estimate of $65 million (excluding tariffs).
However, adjusted EPS guidance was lowered to $0.75–$0.95 due to tariff and executive transition costs. Management highlighted ongoing tariff mitigation efforts and expects segment growth to rebound after a softer Q2.
- Tariff impact could further pressure earnings if rates remain high.
- Transformation and commercial initiatives are expected to support segment growth in H2 2025.
Takeaways
Avanos’ Q1 results underscore the company’s ability to drive segment growth and margin expansion, but also highlight the magnitude of external risk from tariffs and regulatory uncertainty.
- Nutrition Outperformance: Specialty nutrition systems remain the core growth engine, with robust organic growth and profitability supporting the company’s long-term thesis.
- Tariff Headwinds Dominate: The $15 million tariff estimate forced an EPS reset, demonstrating the vulnerability of global supply chains and the importance of mitigation levers.
- Execution Reset Under New Leadership: The new CEO’s commercial focus and transformation track record will be key as Avanos navigates macro and regulatory turbulence through 2025.
Conclusion
Avanos enters the remainder of 2025 with strong segment fundamentals and a sharpened organizational focus, but faces a challenging external environment as tariff costs mount. The company’s ability to execute on mitigation strategies and drive commercial innovation under new leadership will determine whether it can sustain growth and margin gains in the face of persistent macro headwinds.
Industry Read-Through
Avanos’ experience this quarter is a cautionary signal for medtech peers and broader healthcare suppliers: Tariff volatility and regulatory risk can quickly overwhelm operational gains, especially for companies with globalized supply chains and exposure to China-origin goods. Segment realignment and embedded transformation programs may become increasingly necessary as industry players seek to protect margins and maintain capital flexibility. The sector should expect continued pricing pressure in commoditized product lines and heightened importance of supply chain agility and government relations as policy shifts accelerate.